Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.

British journal of pharmacology - 1 Nov 2015

Faouzi Malika, Starkus John, Penner Reinhold

Abstract excerpt

BACKGROUND AND PURPOSE: Kv 1.3 potassium channels are promising pharmaceutical targets for treating immune diseases as they modulate Ca(2+) signalling in T cells by regulating the membrane potential and with it the driving force for Ca(2+) influx. The antimycobacterial drug clofazimine has been demonstrated to attenuate antigen-induced Ca(2+) oscillations, suppress cytokine release and prevent skin graft...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium Channel Blockers
Share to HEK293 Cells
Share to Ion Channel Gating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kinetics

Share to Mutation

Share to Patch-Clamp Techniques

Source

Open in PubMed Open full text

Identifiers

PMID: 26276903
DOI: 10.1111/bph.13283
PMCID: PMC4687807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.PMID 26276903Read ↗

Kv1.3 in the spotlight for treating immune diseasesSemantic proximity Read ↗

Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.Semantic proximity Read ↗

Ca2+-Activated K+ Channel KCa3.1 as a Therapeutic Target for Immune Disorders.Semantic proximity Read ↗

Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.Semantic proximity Read ↗

Potassium channels as therapeutic targets for autoimmune disorders.Semantic proximity Read ↗

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.Semantic proximity Read ↗

Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.Semantic proximity Read ↗

Characterization and molecular basis for the block of Kv1.3 channels induced by carvedilol in HEK293 cells.Semantic proximity Read ↗

Up-regulation of Kv1.3 channels by janus kinase 2.Semantic proximity Read ↗

<i>In Silico</i> identification and modelling of FDA-approved drugs targeting T-type calcium channelsSemantic proximity Read ↗

RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels.Semantic proximity Read ↗

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.